Context: Anti-Müllerian hormone (AMH) and AMH type II receptor (AMHR2) are overexpressed in granulosa cells (GCs) from women with polycystic ovary syndrome (PCOS), the most common cause of female infertility.
A nti-Müllerian hormone (AMH), also called Müllerian inhibiting substance, is a 140-kDa glycoprotein, well known for its role during male sexual differentiation (1) . AMH needs to be cleaved to be active, and it exerts its effects by binding to a specific AMH type II receptor (AMHR2). In females, AMH is secreted by granulosa cells (GCs) at a low level in the postnatal period, and levels surge at the time of puberty, before gradually declining throughout reproductive life until menopause (2) . Initiated in primary follicles, the AMH expression is strongest in preantral and small antral follicles and decreases subsequently up to ovulation, becoming nearly undetectable except in cumulus cells (3) . AMH is no longer detected in luteal bodies and atretic follicles. AMHR2 is coexpressed with AMH in GCs of growing follicles (4) . During folliculogenesis, AMH inhibits the initial recruitment of primordial follicles and reduces the sensitivity of growing follicles to follicle-stimulating hormone (FSH), inhibiting in particular the aromatase activity (2) . In addition, AMH is now recognized as an important clinical marker of the size of the ovarian follicle pool and as a predictor of the ovarian response to controlled ovarian hyperstimulation (5) .
Polycystic ovary syndrome (PCOS) is the most common cause of female infertility, affecting 5% to 10% of women of reproductive age worldwide (6) . The 2003 Rotterdam criteria for the diagnosis of PCOS are based on at least two of the following features: an irregular ovulatory function (oligomenorrhea or amenorrhea), the evidence of hyperandrogenism (biological or clinical), and the presence of a polycystic ovarian morphology (7) . In addition, other endocrine disorders, including the hypersecretion of luteinizing hormone (LH) and insulin resistance, are observed in patients with PCOS (8) . Both serum and follicular fluid (FF) AMH levels are increased in women with PCOS (9) , and are correlated with the severity of the disease (10) . We have shown that they are also associated with increased levels of cleaved AMH (11) and an enhancement of the AMHR2 expression (12) , supporting the hypothesis that AMH is most likely involved in the follicular arrest observed in women with PCOS. The rise of serum AMH concentration observed in these patients is due to the large number of small antral follicles, as well as to the enhancement of AMH production per GC (12, 13) . In addition, we have shown that a dysregulation of AMH and AMHR2 genes by LH could contribute to their overexpression. Indeed, LH stimulates the AMH expression in GCs from patients with PCOS (13, 14) , but has no effect in GCs collected from control women. Moreover, AMHR2 messenger RNA (mRNA) levels are not modulated by LH in GCs from women with anovulatory PCOS (14) , whereas they are downregulated in GCs from control women. Other hormones dysregulated in women with PCOS such as steroids might also be involved.
In keeping with this hypothesis, we and others have previously demonstrated that the androgen receptor (AR) (12) and the estrogen receptor (ESR) 2 (15) are differentially expressed in GCs from control women and women with PCOS.
The aim of this work was to compare the regulation of the AMH and AMHR2 genes by 5a-dihydrotestosterone (5a-DHT), a nonaromatic androgen, and by estradiol (E2) in GCs from control patients and patients with PCOS. In addition, we related our results to the expression levels of AR, ESR1, and ESR2 genes by GCs in these two groups of patients.
Materials and Methods

Subjects
Women undergoing in vitro fertilization (IVF) were included in this study: 48 in the control group and 37 in the PCOS group. All women in the control group met the following inclusion criteria: (1) age between 20 and 40 years; (2) both ovaries present, with no morphological abnormalities, adequately visualized by transvaginal ultrasound scans; (3) menstrual cycle length range between 26 and 30 days; (4) no current or past diseases affecting the ovaries or gonadotropin and sex steroid secretion, clearance, or excretion; (5) no clinical signs of hyperandrogenism; and (6) no polycystic ovary morphology at ultrasonography. Infertility was due either to tubal or sperm abnormalities. Women with PCOS were selected according to the Rotterdam criteria (7): ovulatory disturbance, mainly oligomenorrhea and amenorrhea; polycystic ovary morphology at ultrasonography or hyperandrogenism. Based on our previous findings that the AMH/AMHR2 system is dysregulated by LH only in GCs of women with anovulatory PCOS with polycystic ovary morphology (14) , we decided to include only these patients. The investigation received the approval of our internal institutional review board, and all women signed an informed consent before participating.
Collection and culture of human mural lutein GCs
After oocyte isolation, FF from every patient was centrifuged separately to isolate GCs, as previously described (14) . The supernatants were stored at 280°C, and the cells contained in the pellet were purified on a Percoll gradient to remove red blood cells. Resuspended cells were counted and stored at 220°C in RLT buffer (Qiagen, Valencia, CA) for RNA extraction. When the number of cells was sufficient, part of GCs was seeded at 3 3 10 5 cells/well in six-well plates in Dulbecco's modified Eagle medium/F12 (Invitrogen, Carlsbad, CA) containing 10% fetal calf serum (Invitrogen), and antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin; Invitrogen). The next day, GCs were serum starved during 3 hours and then treated for 48 hours with 5a-DHT (10 26 M or 3 3 10 28 M) or with E2 (10 26 M) (stock solutions at 6 3 10 23 M in ethanol, diluted in the culture medium to the wanted final concentration), or the same volume of ethanol, in Dulbecco's modified Eagle medium/F-12 without phenol red (Invitrogen) and fetal calf serum. Depending on the number of cells, we performed a single treatment (control medium and 5a-DHT or E2) or two treatments (control medium, 5a-DHT, and E2).
RNA analysis
Total RNAs were extracted from GCs using the RNA Plus extraction kit (Qiagen). Reverse transcription was performed in a total volume of 20 mL with the Omniscript reverse transcription kit (Qiagen) using 1 mg RNA, Omniscript reverse transcription, and both oligo-dT primers and random hexamers, as recommended by the manufacturer.
The quantification of AMH, AMHR2, ESR1, ESR2, AR, and housekeeping gene (Ribosomal protein L13a, RPL13a) mRNAs was performed by real-time polymerase chain reaction (PCR) using TaqMan PCR method in noncultured GCs from control women and women with PCOS (n = 19 for both groups). The AMH expression was also measured in GCs from control women treated with 5a-DHT (10 26 M, n = 13 or 3 3 10 28 M, n = 4) or E2 (10 26 M) and in GCs from women with PCOS treated with 5a-DHT (10 26 M, n = 8 or 3 3 10 28 M, n = 4) or with E2 (10 26 M, n = 10). The AMHR2 expression was quantified in GCs from control women and women with PCOS treated with 5a-DHT (10 26 M, n = 10 and n = 9, respectively) or with E2 (10 26 M, n = 8 and n = 9, respectively). The primers and the Universal ProbeLibrary probes (Roche Diagnostics, Indianapolis, IN) used to amplify these genes are indicated in Supplemental Table 1 . Real-time PCR was performed in duplicates with one-fifth dilution of the complementary DNAs using the LightCycler 480 Probes Master kit (Roche Diagnostics). The PCR protocol was the same, as previously described (14) . Data were obtained as Ct values (Ct = cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine DCt values [DCt = (Ct of the target gene) 2 (Ct of the reference gene)]. Results between control women and women with PCOS were compared using 2 2DDCt method (16).
Hormonal measurements in serum and FF
Serum and FF assays were performed for all the women included into the study (n = 48 for controls; n = 37 for women with PCOS). Serum hormone assays were performed at cycle day 3 at the biomedical analysis laboratory of Antoine Béclère Hospital (17) .
The 5a-DHT and testosterone (T) FF concentrations were assayed simultaneously by gas chromatography-mass spectrometry, according to the protocol described by Giton et al. (18) . In short, 5a-DHT and T were derivatized with pentafluorobenzoyl chloride (Sigma-Aldrich, St. Louis, MO). Final extracts were reconstituted in iso-octane and transferred for injection into a 6890N GC system (Agilent Technologies, Les Ulis, France) using a 50% phenylmethylpolysiloxane VF-17MS capillary column (Agilent Technologies). A HP5973 (Agilent Technologies) quadrupole mass spectrometer equipped with a chemical ionization source and operating in single-ion monitoring mode was used for detection. The linearity of steroid measurement was confirmed by plotting the ratio of the steroid peak response/internal standard peak response, to the concentration of steroid for each calibration standard. Under our study conditions, the low limits of quantification of these steroids were in ng/mL: 0.002 (5a-DHT), 0.010 (T), with coefficients of variation (CVs) (17 runs) between 7% and 12.5%. The interassay CVs (17 runs) of the control sera of low concentrations (in ng/mL) of 5a-DHT (0.19) and T (0.48) were between 3.2% and 4.7%. The interassay CVs (17 runs) of the control sera of middle concentrations (in ng/mL) of 5a-DHT (0.48) and T (2.47) were between 2.4% and 4.1%. The interassay CVs (17 runs) of the control sera of high concentrations (in ng/mL) of 5a-DHT (1.49) and T (5.95) were between 2.2% and 3.9%.
The sex hormone-binding globulin concentration was measured using an immunoradiometric assay (Beckman Coulter Immunotech, Marseille, France). The interassay CVs (13 runs) were 4.7%, 3.9%, and 3.8%, respectively, for serum control levels 20.4 nM, 57.5 nM, and 89.4 nM. The free T levels were calculated as previously described (19) . The results were normalized with the total FF protein content (17) .
Statistics
Statistical analyses were performed with the GraphPad Prism 6.0 software (GraphPad Software, La Jolla, CA). A MannWhitney U test was used to compare the clinicopathological features, and the AMH, AMHR2, ESR, and AR mRNA expression of control and women with PCOS. Spearman rank correlation test was used to determine the correlation between AMH serum concentration and the ESR1/ESR2 mRNA ratio. The nonparametric Wilcoxon signed-rank test was used to compare the differences of mRNA expression between cells cultured in control medium and with 5a-DHT or E2, in both groups.
Results
Population
The main clinical, biological, and ultrasonographic characteristics of control and women with anovulatory PCOS (n = 48 for controls and n = 37 for women with PCOS) are summarized in Table 1 . The two groups were comparable for body mass index, but the median age of women with PCOS was significantly lower than controls. At day 3 of the menstrual cycle, women in the PCOS group had a significantly higher antral follicular count, as well as higher serum FSH, LH, and AMH concentrations, and LH/FSH ratio. However, day 3 serum E2 levels were comparable between the two groups ( Table 1) . We also measured steroid levels in FF using gas chromatography-mass spectrometry to determine the steroid environment of GCs. Mean T, 5a-DHT, and free T concentrations were significantly higher in PCOS patients than in controls. However, sex hormone-binding globulin concentrations between the two groups were comparable ( Table 2) .
Comparison of the AMH, AMHR2, AR, ESR1, and ESR2 mRNA content in GCs from control and women with PCOS
We studied the expression of AMH, AMHR2, and steroid receptors in noncultured GCs collected from control women and women with PCOS (n = 19 for both groups) by real-time reverse transcription PCR. As previously described (12) , AMH, AMHR2, and AR mRNA levels were significantly upregulated in GCs from patients with PCOS (7.2-, 3-, and 1.4-fold increases, respectively) (Fig. 1A, 1B, and 1E) . Interestingly, the ESR1 mRNA expression was higher (1.9-fold) in GCs from women with PCOS compared with controls (Fig. 1C) , whereas the ESR2 mRNA levels were similar in both groups (Fig. 1D) . Consistent with this result, the ESR1/ESR2 mRNA expression ratio was significantly increased in patients with PCOS compared with control women (3.8 6 0.38 versus 2.54 6 0.39, P , 0.05, respectively).
The Spearman rank test showed no correlation between the expression of AR and serum AMH levels in patients with PCOS. However, a significant positive linear correlation was observed between serum AMH levels and the ESR1/ESR2 ratio in women with PCOS (Fig. 1F) .
Effect of 5a-DHT and E2 on the AMH and AMHR2 mRNA expression by GCs from control and women with PCOS
We then compared the effects of androgens and E2 on the AMH and AMHR2 expression by GCs from control women and women with PCOS. To discriminate the effects of these steroids, we used 5a-DHT, a nonaromatic androgen. A 48-hour treatment with 5a-DHT (10 26 M and 3 3 10 28 M) had no effect on the AMH expression by GCs from control women (n = 13 and n = 4, respectively) ( Fig. 2A and 2B ), but a significant increase of AMH mRNA levels in GCs from patients with PCOS was obtained with both a high (10
and a lower concentration of 5a-DHT (3 3 10 28 M) (2.3-fold increase, n = 8, Fig. 2A and 1 .4-fold increase, n = 4, Fig. 2B , respectively). As previously described by our group (20) , AMH mRNA levels decreased significantly in control women in the presence of E2 (1.4-fold decrease; n = 13, Fig. 2C ) at 10 26 M, which corresponds to the steroid concentration present in the fluid of mature follicles (18) . In contrast, E2 treatment of GCs from women with PCOS (n = 10) had no effect (Fig. 2C) . We also investigated the regulation of AMHR2 mRNA levels by 5a-DHT and E2. The 5a-DHT had no effect on the AMHR2 expression by GCs from control women (n = 10) and women with PCOS (n = 9) (Fig. 3A) . Interestingly, AMHR2 mRNA levels significantly decreased in GCs from control women (n = 8) in the presence of E2 (1.8-fold decrease) (Fig. 3B) . In contrast, E2 treatment had no effect on the AMHR2 expression by GCs from PCOS patients (n = 9) (Fig. 3B ).
Discussion
The aim of our study had been to assess whether steroids are involved in the overexpression of the AMH/AMHR2 system in GCs from women with PCOS. We have shown that 5a-DHT has no effect on the AMH and AMHR2 expression in GCs from control women but upregulates AMH mRNA levels in GCs from patients with PCOS. In addition, the inhibitory effect of E2 on the AMH and AMHR2 expression, normally observed in control women, is not found in GCs from women with PCOS. In keeping with this differential effect of androgens and E2 on the AMH/AMHR2 system between the two groups of patients, the AR and ESR1 are overexpressed in GCs from women with PCOS.
All of the patients with PCOS selected for our study were diagnosed according to the Rotterdam criteria.
However, on the basis of our previous findings that the AMH/AMHR2 system is dysregulated by LH only in GCs of women with anovulatory PCOS with polycystic ovary morphology (14) , we chose to include only these patients. One limitation of our study is that we used luteinized mural GCs from women undergoing IVF Figure 1 . Comparison of (A) AMH, (B) AMHR2, (C) ESR1, (D) ESR2, and (E) AR mRNA expression in noncultured GCs from control women (n = 19) and women with PCOS (n = 19). mRNA expression levels are presented as 2 2DCt normalized to RPL13a and are compared between control women and women with PCOS using the 2 2DDCt method. The horizontal lines correspond to the mean and standard error of the mean. Results were analyzed by Mann-Whitney U test for unpaired comparisons; *P , 0.05; **P , 0.01; ***P , 0.001 versus control medium. (F) Scatterplot representing the relationship between the individual AMH serum concentrations and ESR1/ESR2 mRNA levels in 19 women with PCOS. Correlation coefficient (r) and the significance level of the Spearman rank test (P) are shown in the upper left corner.
treatment, which poorly expressed AMH and AMHR2 mRNAs. However, they are quantifiable by real-time reverse transcription PCR (12) , and the cells are responsive to steroids (20) . Cumulus GCs removed from oocytes before intracytoplasmic sperm injection could represent a better model, but, due to the fact that we selected women with anovulatory PCOS, they generally do not also need intracytoplasmic sperm injection.
Most studies report the existence of a relationship between androgens and AMH. In rodents and in humans, T treatment has been shown to decrease the AMH expression in vivo (19, 21) . However, the observed effect could be mediated by E2, produced via aromatization of was studied by reverse transcription and real-time PCR. AMH mRNA expression levels are presented as 2 2DCt normalized to RPL13a and are compared between control women and women with PCOS using the 2 2DDCt method. The horizontal lines correspond to the mean and standard error of the mean. n represents the number of women. Results were analyzed by the Wilcoxon signed-rank test for paired comparisons; *P , 0.05; **P , 0.01 versus control medium. Figure 3 . Effect of 5a-DHT and E2 on AMHR2 mRNA levels in GCs from control women and women with PCOS. The expression of AMHR2 in GCs after 48 hours of culture in control medium, with (A) 5a-DHT (10 26 M) (A) or with (B) E2 (10 26 M), was studied by reverse transcription and real-time PCR. AMHR2 mRNA expression levels are presented as 2 2DCt normalized to RPL13a and are compared between control women and women with PCOS using the 2 2DDCt method. The horizontal lines correspond to the mean and standard error of the mean. n represents the number of women. Results were analyzed by the Wilcoxon signed-rank test for paired comparisons; **P , 0.01 versus control medium.
T in GCs. In patients with PCOS, a positive correlation between androgens and AMH levels has been reported by several authors (22) . However, because androgens are suspected to be responsible for the enhanced recruitment of primordial follicles, the increased AMH levels could be due to the subsequent enhanced number of follicles. Altogether, in vivo studies do not discriminate between a direct and an indirect effect of androgens on the AMH and AMHR2 expression. Therefore, we decided to address this question using an in vitro model. We have shown that 5a-DHT has no effect on AMH and AMHR2 mRNA levels in GCs from control women, whereas 5a-DHT upregulates the AMH expression in GCs from women with PCOS. In contrast, Crisosto et al. (23) reported a decrease of AMH mRNA levels by T in bovine GCs from small follicles. More recently, Zhang et al. (24) observed a stimulatory effect of T on AMH mRNA levels in GCs taken from mouse antral follicles. These contradictory results could be explained by an estrogen effect due to the use of T, and by the stage of GC differentiation because the AR is more expressed by GCs of growing follicles (12, 25) . We have also confirmed a higher expression level of the AR in GCs collected from patients with PCOS (12), a finding already reported in GCs taken from monkeys treated with androgens (25) . This could explain the differential effect of androgen between control and PCOS GCs. In keeping with the stimulatory effect of 5a-DHT on the AMH expression observed in PCOS GCs, the positive correlation between serum androgens and AMH is mainly observed in women with PCOS (22) . Furthermore, in oligo-anovulatory women with polycystic ovarian morphology, serum AMH concentrations are higher in hyperandrogenic women compared with the ones with normal androgen levels (26) , and androgen-lowering treatments decrease AMH levels (27) . Therefore, our study suggests that androgens could participate in the overexpression of AMH in women with PCOS, by enhancing the recruitment of primordial follicles and by stimulating the AMH expression by GCs.
In vivo studies have shown a repressing effect of E2 on the AMH expression (4), but the finding can be confounded by the fact that FSH by increasing E2 production can also impact the AMH expression. Our in vitro model confirmed that E2 reduces the AMH expression in GCs of control women (20) and showed that it also has a repressive effect on AMHR2 mRNA levels. In contrast, E2 does not regulate these genes in GCs from women with PCOS. We had previously shown in the KK1 mouse GC line that E2 represses the AMH transcription when the ESR1/ESR2 expression ratio is ,1, whereas it has an opposite effect when the ESR1/ESR2 ratio is .1 (20) . Similarly, the regulation of the AMH expression by E2 might depend upon a certain ESR1/ESR2 expression ratio in vivo. In GCs from control women, the ESR1/ ESR2 ratio possibly induces a negative effect of E2 on the AMH expression, whereas in GCs from women with PCOS the overexpression of ESR1 prevents this inhibitory effect of E2 on AMH mRNA levels. In keeping with this result, our study showed that serum AMH concentration in patients with PCOS is positively correlated with the ESR1/ESR2 mRNA ratio. Jakimiuk et al. (15) also reported an increase of the ESR1/ESR2 ratio in GCs from PCOS, due to a downregulation of the ESR2 expression. This discrepancy could be explained by the use of GCs from women in the follicular phase of their menstrual cycle who mainly express ESR2 (28), whereas, in our GC model, ESR1 is predominant under the action of exogenous gonadotropins used in the IVF protocol.
The frequent dysregulation of reproductive hormones in women with PCOS might also participate in the overexpression of the AMH/AMHR2 system in their GCs. We have previously shown that both the rise of LH levels often encountered in women with PCOS and the inhibition of LH repressive action on the AMH/AMHR2 system participate in its overexpression in GCs (14) . Interestingly, in this study, the LH/FSH ratio is higher in PCOS patients than in control women. Androgen and E2 production are also often dysregulated in women with PCOS (22) . Hyperandrogenia, one of the diagnostic criteria of PCOS, is the consequence of thecal cell hyperplasia and an increase of their steroidogenic enzyme activity (29) , which is amplified by the LH excess (30) . The inhibition of FSH-induced ovarian E2 production by GCs from women with PCOS observed in large antral follicles (22) is due to both the high T levels that repress aromatase activity (31) and the overexpression of AR, which increases their sensitivity to androgens. The overexpression of the AMH/AMHR2 system in GCs from women with PCOS could thus be due to the respective increased and reduced serum androgens and FF E2 levels often encountered in these patients, and to the dysregulation of their effects on GCs. Serum androgen levels are not part of the routine workup of PCOS patients at our IVF center, but the measurement of free and total T concentrations in FF indicates that androgen levels are higher in women with PCOS. Finally, because AMH has been shown to inhibit E2 production (2) and to increase gonadotropin releasing hormone-dependent LH pulsatility and secretion (32) , its overexpression could further intensify this vicious cycle (Fig. 4) .
There is strong evidence to suggest that the overexpression of the AMH/AMHR2 system could disturb follicle selection and induce anovulation in women with PCOS. Indeed, by inhibiting follicle sensitivity to FSH, and by repressing the aromatase and LHR expression (33), AMH could prevent follicles from reaching dominance, thus causing anovulation. In keeping with this hypothesis, the decline in the AMH and AMHR2 expression during late follicular growth phase corresponds to the increase of E2 production and the selection of follicles for dominance (34) . The fact that the AMH/ AMHR2 system is dysregulated by LH only in GCs from anovulatory women with PCOS, and the fact that serum AMH levels are lower in women who have PCOS with a hyperandrogenic normo-ovulatory phenotype compared with women with a nonhyperandrogenic oligo-anovulatory phenotype, indicate that the factors involved in the regulation of AMH are related to menstrual disorders in patients with PCOS.
In summary, our study revealed a dysregulation of the androgen and estrogen receptor expression in GCs collected from women with PCOS. The resulting modified receptivity of GCs to androgen and E2 leads to an overexpression of the AMH/AMHR2 system. When present, a dysregulation of LH, androgens, and E2 synthesis could further exacerbate the phenomenon. The subsequent absence of inhibition of the AMH/AMHR2 system during follicle maturation could prevent dominant follicle selection, and lead to anovulation in women with PCOS. Although many aspects of the AMH/AMHR2 system regulation are still to be elucidated, our study provides new insights into the dysregulation of that system in patients with PCOS. Figure 4 . Diagram illustrating the regulation of the AMH/AMHR2 system in women with PCOS. In women with PCOS, the AMH expression increases with rising levels of LH and T and as the result of the stimulatory effects of these as well as the absence of the inhibitory effect of E2. Likewise, the AMHR2 mRNA levels increase in the absence of LH and E2 repressive actions. The overexpression of AMH intensifies the vicious cycle by inhibiting E2 production and by stimulating gonadotropin releasing hormone-dependent LH pulsatility and secretion. doi: 10.1210/jc.2017-00308 https://academic.oup.com/jcem
